We included 226 patients after initially screening 507 patients excluding breast cancer patients untreated with chemotherapy (n=180), primary breast disease (n=45), HER2 positive disease (n=37), and 19 patients with insufficient data and those who received eribulin as combined chemotherapies were excluded (Figure 1). This evidence concerns the gene ERBB2 and breast cancer.